

Assay Development for Phagocytosis Activity Evaluation [†]

Elena Lysakova ^{*}, Alexander Shumeev, Victor Laktyushkin, Sergey Chuvpilo and Stanislav Rybtsov

Sirius University of Science and Technology; email1@email.com (A.S.); email2@email.com (V.L.); email3@email.com (S.C.); email4@email.com (S.R.)

^{*} Correspondence: lysakova.ev@learn.siriusuniversity.ru

[†] Presented at the 2nd International Electronic Conference on Microbiology, 1–15 December 2023; Available online: <https://ecm2023.sciforum.net>.

Abstract: The efficiency of phagocytic activity is a significant organism's indicator which decreases with the aging of the immune system. The medications are able to influence phagocytosis, having a blocking or activating effect, and therefore are important modulators of immune function. We are developing an ex vivo assay indispensable for medication screening in human and *Macaca fascicularis* whole blood. For assay verification several published control drugs were successfully used. This assay assists to find medications for enhancing the immune response in the elderly and to provide a deep comprehension of fundamental process of immune system aging.

Keywords: phagocytosis; senescence; immune system; immune response; monkey; drugs

1. Introduction

The increased risk of developing age-related diseases in the elderly is associated with an imbalance and deficiency of the immune response, therefore, specific treatment and vaccination approaches should be developed. The efficiency of phagocytic activity is a significant organism's indicator which decreases with the aging of the immune system. The medications are able to influence phagocytosis, having a blocking or activating effect, are important modulators of immune function. We are developing an ex vivo assay indispensable for medication screening in human and *Macaca fascicularis* whole blood. *M. fascicularis* is the well-recognized preclinical model having human-like immune responses. For assay verification several published control drugs [1] were successfully used for blocking and acceleration of phagocytosis. Experiments evaluating human and animal phagocytosis indices at different ages will provide statistical standards to be used for medication preclinical and clinical trials. This assay assists to find medications for enhancing the immune response and antigen presentation in the elderly. Moreover, screening of medications, having impact to phagocytosis and further researches of their mechanisms assist to a deep comprehension of fundamental process of immune system aging, and provide a perspective for immune response correction.

2. Materials and Methods

The object for phagocytosis was *E. coli* stained in house with FITC (Lumiprobe) for 3 h, 37 °C. Phagocytosis was carried out in whole blood without adhesion [2] under near physiological conditions (T = 37 °C, 5% CO₂). After 1 h incubation with *E. coli*, cells were treated with Protein transport inhibitor, containing monensin (BD GolgiStop), according to the instruction, or placed on ice, or treated with combination of lidocaine (0.1–3 mg/mL)—epinephrine (0.34–10.2 μM) [1] for 5 min. Then the erythrocytes were lysed with BD Pharm Lyse according to the instruction. Besides, cells were pre-treated with these agents for 5 min before adding bacteria. Sample analysis was performed on a BD LSRFortessa flow cytometer. To correctly identify leucocytes, CD45 APC-eFluor780 (HI30, eBioscience; 1:100) was used.

Citation: Lysakova, E.; Shumeev, A.; Laktyushkin, V.; Chuvpilo, S.; Rybtsov, S. Assay Development for Phagocytosis Activity Evaluation. *Biol. Life Sci. Forum* **2023**, *31*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor(s): Name

Published: date



Copyright: © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

3. Results and Discussion

Pre-treated with different agents blood cells were incubated with *E. coli* as described; after that percentage of phagocytosed cells (PC; activated monocytes or granulocytes, as the most prominent phagocytosed populations) was evaluated (Figure 1).




Figure 1. Evaluation of activated cells percentage, while treated for 5 min with phagocytic activity inhibitors before phagocytosis modulation. * BD GolgiStop = BD GolgiStop™ Protein Transport Inhibitor (Containing Monensin). L = Lidocaine concentration (mg/mL). E = Epinephrine concentration (μM).

In comparison to non-treated cells (PC ~ 33%), treated cells' phagocytic activity plummeted (PC 4.6–20.8%), and lidocaine-epinephrine treatment showed dose-dependent decrease, effectively blocked phagocytosis in the same manner as commercial GolgiStop in optimal concentration. This trend was linear for both granulocytes and monocytes ($R^2 = 0.972$ and $R^2 = 0.997$, respectively, Figure 2).




Figure 2. Linear dependence of activated cells percentage on lidocaine-epinephrine concentrations.

Moreover, treatment after 1 h incubation with *E. coli*, was indistinguishable from control sample without inhibitors of phagocytosis (Figure 3).




Figure 2. Linear dependence of activated cells percentage on lidocaine-epinephrine concentrations.

Despite there was no difference, it can be used in modifications of phagocytic dynamic test where both engulfed and adhered bacteria are detected in defined timelapse. In case of phagocytosis was stopped on ice, percentage of PC was lower in comparison with treated and non-treated samples, and it can be supposed that cells undergo degranulation and cell death on ice. Further analysis confirmed that degranulation and death of phagocytosed cells on ice occurs, and that additionally validates usage of chemical agents to block phagocytosis.

4. Conclusions

Lidocaine-epinephrine mixture inhibits phagocytosis and, if necessary, can be used as a stop-reagent as a cheaper and effective analogue to commercial reagents and ice. Phagocytic activity evaluation by FITC-conjugated bacteria and developed protocol in whole blood suggested to use as an essential part for medication screening. Validation of perspective medications is recommended for elderly people whose phagocytosis is impaired. Moreover, phagocytosis testing in whole blood under near physiological conditions offers useful and feasible approach for a personalized medicine.

Author Contributions:

Funding:

Institutional Review Board Statement:

Informed Consent Statement:

Data Availability Statement:

Acknowledge: The work was carried out with the support of the Russian Science Foundation, project No. 23-15-00443 (<https://rscf.ru/project/23-15-00443>).

Conflicts of Interest:

References

1. Azuma, Y.; Wang, P.L.; Shinohara, M.; Ohura, K. Differentiation by in vitro treatment of lidocaine-epinephrine and prilocaine-felypressine in neutrophils. *Immunol. Lett.* **2001**, *77*, 151–158.
2. Garcia-Seyda, N.; Seveau, V.; Manca, F.; Biarnes-Pelicot, M.; Valignat, M.P.; Bajenoff, M.; Theodoly, O. Human neutrophils swim and phagocytise bacteria. *Biol. Cell* **2021**, *113*, 28–38.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.